The role of the microbiome in pancreatic cancerpersonalized therapy prognosis
Recruiting
- Conditions
- K80-K87Disorders of gallbladder, biliary tract and pancreas
- Registration Number
- DRKS00028995
- Lead Sponsor
- niversitätsklinikum Heidelberg. Dept. Allgemeine, Viszerale und Transplantations Chirurgie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Pancreatic diseases (pancreatitis, IPMN, PDAC).
Exclusion Criteria
Neuroendocrine tumors, not pancreatic disease.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Determination of the fecal, and intra-tumoral microbiome in patients with tumor precursor lesions (pancreatitis and IPMN patients) and in pancreatic carcinoma patients. Stool samples from healthy volunteers and healthy pancreatic tissue from the transplantation programs will be used as microbiome controls. Comparisons will be made between the different bacterial strains (the microbiome) and the pancreatic cancer prognosis. Stool samples are collected just before surgery and tissue are collected during the surgery. Healthy volunteers serve as controls for the stool samples. Unused pancreatic tissue from the transplant program serves as control tissue. The respective microbiome will be determined by 16s sequencingon stool and tissue and compared to disease (pancreatitis, IPMN versus pancreatic cancer).
- Secondary Outcome Measures
Name Time Method Determination of risk bacteria strains in stool and/or tissue of pancreatitis and IPMN patients with increased pancreatic cancer risk.